[Evaluation of clinical data and immuno-modulating treatment of patients with oral lichen planus].
The number of patients with oral lichen planus increases all over the world. The treatment of this disease is not yet definitive. Although the etiology is not clear until now increasing number of data show relations between the environment and immune-responsiveness. In this study the data (medical history and laboratory test results) of 33 lichen oris patients were processed. The prevalence of diabetes mellitus was much higher in lichen patients, than in persons without lichen oris. Likewise, higher transaminase serum levels in lichen patients were found, and there were two HCV positive cases among them. In contrast to the literary data instead of immune suppressive treatment the immune modulant treatment has been applied: 78% of beta levamisole treated and 90% of interferon alpha treated patients were cured. Only lichen patients without symptoms of general diseases could be stabilized.
Kövesi
G
G
Semmelweis Egyetem Parodontológiai Klinika, Budapest.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D048909:Diabetes Complications; D005260:Female; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007978:Levamisole / Q000627:therapeutic use*; D008010:Lichen Planus / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016898:Interferon-alpha; D007978:Levamisole; D000637:Transaminases